6.0.0.0 Ref­er­ences

  1. Amer­i­can Di­a­betes As­so­ci­a­tion. Eco­nom­ic costs of di­a­betes in the U.S. in 2017. Di­a­betes Care 2018;41:917–928
  2. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Im­per­a­tore G, Gregg EW. Achieve­ment of goals in U.S. di­a­betes care, 1999–2010. N Engl J Med 2013;368:1613–1624
  3. Buse JB, Gins­berg HN, Bakris GL, et al.; Amer­i­can Heart As­so­ci­a­tion; Amer­i­can Di­a­betes As­so­ci­a­tion. Pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar dis­eases in peo­ple with di­a­betes mel­li­tus: a sci­en­tific state­ment from the Amer­i­can Heart As­so­ci­a­tionand the Amer­i­can Di­a­betes As­so­ci­a­tion. Di­a­betes Care 2007;30:162–172
  4. Gaede P, Lund-‍An­der­sen H, Parv­ing H-H, Ped­er­sen O. Ef­fect of a multifac­torial in­ter­ven­tion on mor­tal­i­ty in type 2 di­a­betes. N Engl J Med 2008;358:580–591
  5. Caven­der MA, Steg PG, Smith SC Jr, et al.; REACH Reg­istry In­ves­ti­ga­tors. Im­pact of di­a­betes mel­li­tus on hos­pi­tal­iza­tion for heart fail­ure, car­dio­vas­cu­lar events, and death: out­comes at 4 years from the Re­duc­tion of Atherothrom­bo­sis for Con­tin­ued Health (REACH) reg­istry. Cir­cu­la­tion 2015;132:923–931
  6. McAl­lis­ter DA, Read S, Kerssens J, et al. In­ci­dence of hos­pi­talisation for heart fail­ure and case-‍fa­tal­i­ty among 3.25 mil­lion peo­ple with and with­out di­a­betes. Cir­cu­la­tion. 27 June 2018 [Epub ahead of print]. DOI: 10.1161/ CIR­CU­LA­TION­A­HA.118.034986
  7. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veld­huisen DJ. Heart fail­ure with pre­served

    ejec­tion frac­tion: from mech­a­nisms to ther­a­pies. Eur Heart J 2018;39:2780–2792

  8. Zin­man B, Wan­ner C, Lachin JM, et al.; EMPA- REG OUT­COME In­ves­ti­ga­tors. Em­pagliflozin, car­dio­vas­cu­lar out­comes, and mor­tal­i­ty in type 2 di­a­betes. N Engl J Med 2015;373:2117– 2128
  9. Neal B, Perkovic V, Ma­haf­fey KW, et al.; CAN­VAS Pro­gram Col­lab­o­ra­tive Group. Canagliflozin and car­dio­vas­cu­lar and renal events in type 2 di­a­betes. N Engl J Med 2017;377:644–657
  10. Fitch­ett D, But­ler J, van de Borne P, et al.; EMPA-‍REG OUT­COME® trial in­ves­ti­ga­tors. Ef­fects of em­pagliflozin on risk for car­dio­vas­cu­lar death and heart fail­ure hos­pi­tal­iza­tion across the spec­trum of heart fail­ure risk in the EMPA- REG OUT­COME® trial. Eur Heart J 2018;39:363– 370
  11. Blood Pres­sure Low­er­ing Treat­ment Tria­lists’ Col­lab­o­ra­tion. Blood pres­sure-‍low­er­ing treat­ment based on car­dio­vas­cu­lar risk: a metaanal­y­sis of in­di­vid­u­al pa­tient data. Lancet 2014;384: 591–598
  12. Grundy SM, Stone NJ, Bai­ley AL, et al. 2018 AHA/‍ACC/‍AACVPR/‍AAPA/‍ABC/‍ACPM/‍ADA/‍AGS/‍ APhA/‍ASPC/‍NLA/‍PCNA guide­line on the man­age­ment of blood choles­terol: a re­port of the Amer­i­can Col­lege of Car­di­ol­o­gy/Amer­i­can Heart As­so­ci­a­tion Task Force on Clin­i­cal Prac­tice Guide­lines. J Am Coll Car­di­ol. Novem­ber 2018 [Epub ahead of print]. DOI: 10.1016/j. jacc.2018.11.003
  13. Munt­ner P, Colan­to­nio LD, Cush­man M, et al. Val­i­da­tion of the atheroscle­rot­ic car­dio­vas­cu­lar dis­ease Pooled Co­hort risk equa­tions. JAMA 2014; 311:1406–1415
  14. De­Fil­ip­pis AP, Young R, McEvoy JW, et al. Risk score over­es­ti­ma­tion: the im­pact of in­di­vid­u­al car­dio­vas­cu­lar risk fac­tors and pre­ven­tive ther­a­pies on the per­formance of the Amer­i­can Heart As­so­ci­a­tion-‍Amer­i­can Col­lege of Car­di­ol­o­gy-‍ Atheroscle­rot­ic Car­dio­vas­cu­lar Dis­ease risk score in a mod­ern multi-‍eth­nic co­hort. Eur Heart J 2017; 38:598–608
  15. Bo­hu­la EA, Mor­row DA, Giugliano RP, et al. Atherothrom­bot­ic risk stratification and eze­tim­ibe for sec­ondary pre­ven­tion. J Am Coll Car­di­ol 2017; 69:911–921
  16. Bo­hu­la EA, Bonaca MP, Braun­wald E, et al. atherothrom­bot­ic risk stratification and the ef- ficacy and safe­ty of vo­ra­paxar in pa­tients with sta­ble is­chemic heart dis­ease and pre­vi­ous my­ocar­dial in­farc­tion. Cir­cu­la­tion 2016;134: 304–313
  17. de Boer IH, Ban­ga­lore S, Bene­tos A, et al. Di­a­betes and hy­per­ten­sion: a po­si­tion state­ment by the Amer­i­can Di­a­betes As­so­ci­a­tion. Di­a­betes Care 2017;40:1273–1284
  18. Bo­brie G, Gene`s N, Vaur L, et al. Is “iso­lat­ed home” hy­per­ten­sion as op­posed to “iso­lat­ed office” hy­per­ten­sion a sign of greater car­dio­vas­cu­lar risk? Arch In­tern Med 2001;161:2205–2211
  19. Sega R, Fac­chet­ti R, Bombel­li M, et al. Prog­nos­tic value of am­bu­la­to­ry and home blood pres­sures com­pared with office blood pres­sure in the gen­er­al pop­u­la­tion: fol­low-‍up re­sults from the Pres­sioni Ar­te­riose Mon­i­torate e Loro As­so­ci­azioni (PAMELA) study. Cir­cu­la­tion 2005; 111:1777–1783
  20. Om­boni S, Gaz­zo­la T, Cara­bel­li G, Parati G. Clin­i­cal use­fulness and cost ef­fec­tiveness of home blood pres­sure telemon­i­toring: meta-anal­y­sis of ran­dom­ized con­trolled stud­ies. J Hy­per­tens 2013;31:455–467; dis­cussion 467–468
  21. Emdin CA, Rahi­mi K, Neal B, Cal­len­der T, Perkovic V, Patel A. Blood pres­sure low­er­ing in type 2 di­a­betes: a sys­tematic re­view and metaanal­y­sis. JAMA 2015;313:603–615
  22. Ar­guedas JA, Leiva V, Wright JM. Blood pres­sure tar­gets for hy­per­ten­sion in peo­ple with di­a­betes mel­li­tus. Cochrane Database Syst Rev 2013;10:CD008277
  23. Et­te­had D, Emdin CA, Kiran A, et al. Blood pres­sure low­er­ing for pre­ven­tion of car­dio­vas­cu­lar dis­ease and death: a sys­tematic re­view and meta-‍anal­y­sis. Lancet 2016;387:957–967
  24. Brun­stro¨m M, Carl­berg B. Ef­fect of antihy-‍perten­sive treat­ment at dif­ferent blood pres­sure lev­els in pa­tients with di­a­betes mel­li­tus: sys­tematic re­view and meta-‍anal­y­ses. BMJ 2016;352: i717
  25. Ban­ga­lore S, Kumar S, Lobach I, Messer­li FH. Blood pres­sure tar­gets in sub­jects with type 2 di­a­betes mel­li­tus/im­paired fast­ing glu­cose: ob­ser­va­tions from tra­di­tion­al and Bayesian random-ef­fects meta-‍anal­y­ses of ran­dom­ized tri­als. Cir­cu­la­tion 2011;123:2799–2810
  26. Tho­mopou­los C, Parati G, Zanchet­ti A. Ef­fects of blood-‍pres­sure-‍low­er­ing treat­ment on out­come in­ci­dence in hy­per­ten­sion: 10 - should blood pres­sure man­age­ment dif­fer in hy­per­ten­sive pa­tients with and with­out di­a­betes mel­li­tus? Overview and meta-‍anal­y­ses of ran­dom­ized tri­als. J Hy­per­tens 2017;35:922–944
  27. Xie X, Atkins E, Lv J, et al. Ef­fects of in­ten­sive blood pres­sure low­er­ing on car­dio­vas­cu­lar and renal out­comes: up­dat­ed sys­tematic re­view and meta-‍anal­y­sis. Lancet 2016;387:435–443
  28. Cush­man WC, Evans GW, By­ing­ton RP, et al.; AC­CORD Study Group. Ef­fects of in­ten­sive bloodpres­sure con­trol in type 2 di­a­betes mel­li­tus. N Engl J Med 2010;362:1575–1585
  29. Patel A, MacMa­hon S, Chalmers J, et al.; AD­VANCE Col­lab­o­ra­tive Group. Ef­fects of a fixed com­bi­na­tion of perindo­pril and in­da­pamide on macrovas­cu­lar and mi­crovas­cu­lar out­comes in pa­tients with type 2 di­a­betes mel­li­tus (the AD­VANCE trial): a ran­domised con­trolled trial. Lancet 2007;370:829–840
  30. Bakris GL. The im­pli­ca­tions of blood pres­sure mea­sure­ment meth­ods on treat­ment tar­gets for blood pres­sure. Cir­cu­la­tion 2016;134:904–905
  31. Mar­go­lis KL, O’Con­nor PJ, Mor­gan TM, et al. Out­comes of com­bined car­dio­vas­cu­lar risk fac­tor man­age­ment strate­gies in type 2 di­a­betes: the AC­CORD ran­dom­ized trial. Di­a­betes Care 2014; 37:1721–1728
  32. Buck­ley LF, Dixon DL, Wohlford GF IV, Wi­jesinghe DS, Baker WL, Van Tas­sell BW. In­ten­sive ver­sus stan­dard blood pres­sure con­trol in SPRINT-‍ el­i­gi­ble par­tic­i­pants of AC­CORD-‍BP [pub­lished cor­rec­tion ap­pears in Di­a­betes Care 2018;41:2048]. Di­a­betes Care 2017;40:1733–1738
  33. Brouw­er TF, Vehmei­jer JT, Kalk­man DN, et al. In­ten­sive blood pres­sure low­er­ing in pa­tients with and pa­tients with­out type 2 di­a­betes: a pooled anal­y­sis from two ran­dom­ized tri­als. Di­a­betes Care 2018;41:1142–1148
  34. Lamprea-‍Montealegre JA, de Boer IH. Reeval­u­at­ing the ev­i­dence for blood pres­sure tar­gets in type 2 Di­a­betes. Di­a­betes Care 2018;41: 1132–1133
  35. de Boer IH, Bakris G, Can­non CP. in­di­vid­u­alizing blood pres­sure tar­gets for peo­ple with di­a­betes and hy­per­ten­sion: com­par­ing the ADA and the ACC/‍AHA rec­om­men­da­tions. JAMA 2018; 319:1319–1320
  36. Basu S, Suss­man JB, Rig­don J, Steim­le L, Den­ton BT, Hay­ward RA. Benefit and harm of in­ten­sive blood pres­sure treat­ment: deriva­tion and val­i­da­tion of risk mod­els using data from the SPRINT and AC­CORD tri­als. PLoS Med 2017; 14:e1002410
  37. Phillips RA, Xu J, Pe­ter­son LE, Arnold RM, Di­a­mond JA, Schussheim AE. Im­pact of car­dio­vas­cu­lar risk on the rel­a­tive benefit and harm of in­ten­sive treat­ment of hy­per­ten­sion. J Am Coll Car­di­ol 2018;71:1601–1610
  38. Whel­ton PK, Carey RM, Aro­now WS, et al. 2017 ACC/‍AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/‍ASPC/‍NMA/‍PCNA guide­line for the pre­ven­tion, de­tec­tion, eval­u­a­tion, and man­age­ment of high blood pres­sure in adults: a re­port of the Amer­i­can Col­lege of Car­di­ol­o­gy/Amer­i­can Heart As­so­ci­a­tion Task Force on Clin­i­cal Prac­tice Guide­lines. J Am Coll Car­di­ol 2018;71:e127–e248
  39. Wright JT Jr, Williamson JD, Whel­ton PK, et al.; SPRINT Re­search Group. A ran­dom­ized trial of in­ten­sive ver­sus stan­dard blood-‍pres­sure con­trol. N Engl J Med 2015;373:2103–2116
  40. Bed­dhu S, Greene T, Bouch­er R, et al. In­ten­sive sys­tolic blood pres­sure con­trol and in­ci­dent chron­ic kid­ney dis­ease in peo­ple with and with­out di­a­betes mel­li­tus: sec­ondary anal­y­ses of two ran­domised con­trolled tri­als. Lancet Di­a­betes En­docrinol 2018;6:555–563
  41. Sink KM, Evans GW, Shorr RI, et al. Syn­cope, hy­poten­sion, and falls in the treat­ment of hy­per­ten­sion: re­sults from the ran­dom­ized clin­i­cal Sys­tolic Blood Pres­sure In­ter­ven­tion Trial. J Am Geri­atr Soc 2018;66:679–686
  42. Amer­i­can Col­lege of Ob­ste­tri­cians and Gy­ne­col­o­gists’ Task Force on Hy­per­ten­sion in Preg­nan­cy. Hy­per­ten­sion in preg­nancy. Re­port of the Amer­i­can Col­lege of Ob­ste­tri­cians and Gy­ne­col­o­gists’ Task Force on Hy­per­ten­sion in Preg­nan­cy. Ob­stet Gy­necol 2013;122:1122–1131
  43. Aba­los E, Duley L, Steyn DW. Antihy­per­ten­sive drug ther­a­py for mild to mod­er­ate hy­per­ten­sion dur­ing preg­nancy. Cochrane Database Syst Rev 2014;2:CD002252
  44. Al-‍Balas M, Bozzo P, Einar­son A. Use of di­uret­ics dur­ing preg­nancy. Can Fam Physi­cian 2009;55:44–45
  45. Ir­gens HU, Reisaeter L, Ir­gens LM, Lie RT. Long term mor­tal­i­ty of moth­ers and fa­thers after pre-‍eclamp­sia: pop­u­la­tion based co­hort study. BMJ 2001;323:1213–1217
  46. Sacks FM, Svetkey LP, Vollmer WM, et al.; DASH-‍Sodi­um Col­lab­o­ra­tive Re­search Group. Ef­fects on blood pres­sure of re­duced di­etary sodi­um and the Di­etary Ap­proach­es to Stop Hy­per­ten­sion (DASH) diet. N Engl J Med 2001; 344:3–10
  47. James PA, Opar­il S, Carter BL, et al. 2014 ev­i­dence-‍basedguide­line fortheman­age­mentof high blood pres­sure in adults: re­port from the panel mem­bers ap­point­ed to the Eighth Joint Na­tion­al Com­mit­tee (JNC 8). JAMA 2014;311: 507–520
  48. Bakris GL, Weir MR; Study of Hy­per­ten­sion and the Efficacy of Lotrel in Di­a­betes (SHIELD) In­ves­ti­ga­tors. Achiev­ing goal blood pres­sure in pa­tients with type 2 di­a­betes: con­ven­tion­al ver­sus fixed-‍dose com­bi­na­tion ap­proaches. J Clin Hy­per­tens (Green­wich) 2003;5:202–209
  49. Feld­man RD, Zou GY, Van­der­voort MK, Wong CJ, Nel­son SAE, Fea­gan BG. A sim­plified ap­proach to the treat­ment of un­com­pli­cat­ed hy­per­ten­sion: a clus­ter ran­dom­ized, con­trolled trial. Hy­per­ten­sion 2009;53:646–653
  50. Web­ster R, Salam A, de Silva HA, Selak V, Stepi­en S, Ra­japakse S, et al. Fixed low-‍dose triple com­bi­na­tion an­ti­hy­per­ten­sive med­i­ca­tion vs usual care for blood pres­sure con­trol in pa­tients with mild to mod­er­ate hy­per­ten­sion in Sri Lanka: a ran­dom­ized clin­i­cal trial. JAMA 2018;320: 566–579
  51. Ban­ga­lore S, Ka­malakkan­nan G, Parkar S, Messer­li FH. Fixed-‍dose com­bi­na­tions im­prove med­i­ca­tion com­pli­ance: a meta-‍anal­y­sis. Am J Med 2007;120:713–719
  52. Cata­la´-Lo´pez F, Mac´ıas Saint-‍Gerons D,Gonza´lez-‍Berme­jo D, et al. Car­dio­vas­cu­lar and renal out­comes of renin-‍an­giotensin sys­tem block­ade in adult pa­tients with di­a­betes mel­li­tus: a sys­tematic re­view with net­work meta-‍anal­y­ses. PLoS Med 2016;13:e1001971
  53. Palmer SC, Mavridis D, Navarese E, et al. Com­par­a­tive efficacy and safe­ty of blood pres­sure-‍low­er­ing agents in adults with di­a­betesand kid­ney dis­ease: a net­work meta-‍anal­y­sis. Lancet 2015; 385:2047–2056
  54. Barzi­lay JI, Davis BR, Bet­ten­court J, et al.; ALL­HAT Col­lab­o­ra­tive Re­search Group. Car­dio­vas­cu­lar out­comes using dox­a­zosin vs. chlort­ha­li­do­ne for the treat­ment of hy­per­ten­sion in older adults with and with­out glu­cose dis­or­ders: a re­port from the ALL­HAT study. J Clin Hy­per­tens (Green­wich) 2004;6:116–125
  55. Weber MA, Bakris GL, Ja­mer­son K, et al.; AC­COM­PLISH In­ves­ti­ga­tors. Car­dio­vas­cu­lar events dur­ing dif­fering hy­per­ten­sion ther­a­pies in pa­tients with di­a­betes. J Am Coll Car­di­ol 2010;56: 77–85
  56. Ban­ga­lore S, Fakheri R, Toklu B, Messer­li FH. Di­a­betes mel­li­tus as a com­pelling in­di­ca­tion for use of renin an­giotensin sys­tem block­ers: sys­tematic re­view and meta-‍anal­y­sis of ran­dom­ized tri­als. BMJ 2016;352:i438
  57. Carl­berg B, Samuels­son O, Lind­holm LH. Atenolol in hy­per­ten­sion: is it a wise choice? Lancet 2004;364:1684–1689
  58. Yusuf S, Teo KK, Pogue J, et al.; ON­TAR­GET In­ves­ti­ga­tors. Telmis­ar­tan, ramipril, or both in pa­tients at high risk for vas­cu­lar events. N Engl J Med 2008;358:1547–1559
  59. Fried LF, Emanuele N, Zhang JH, et al.; VA NEPHRON-‍D In­ves­ti­ga­tors. Com­bined an­giotensin in­hi­bi­tion for the treat­ment of di­a­bet­ic nephropa­thy. N Engl J Med 2013;369:1892–1903
  60. Makani H, Ban­ga­lore S, Des­ouza KA, Shah A, Messer­li FH. Efficacy and safe­ty of dual block­ade of the renin-‍an­giotensin sys­tem: meta-‍anal­y­sis of ran­domised tri­als. BMJ 2013;346:f360
  61. Zhao P, Xu P, Wan C, Wang Z. Evening ver­sus morn­ing dos­ing reg­i­men drug ther­a­py for hy­per­ten­sion. Cochrane Database Syst Rev 2011; 10:CD004184
  62. Her­mi­da RC, Ayala DE, Mojo´n A, Ferna´ndez JR. Influence of time of day of blood pres­sure-‍low­er­ing treat­ment on car­dio­vas­cu­lar risk in hy­per­ten­sive pa­tients with type 2 di­a­betes. Di­a­betes Care 2011;34:1270–1276
  63. Nils­son E, Gas­pari­ni A, Arnlov J, et al. In­ci­dence and de­ter­mi­nants of hy­per­kalemia and hy­pokalemia in a large health­care sys­tem. Int J Car­di­ol 2017;245:277–284
  64. Ban­dak G, Sang Y, Gas­pari­ni A, et al. Hy­per­kalemia after ini­ti­at­ing renin-‍an­giotensin sys­tem block­ade: the Stock­holm Cre­a­ti­nine Mea­sure­ments (SCREAM) pro­ject. J Am Heart Assoc 2017; 6:e005428
  65. Hugh­es-‍Austin JM, Rifkin DE, Beben T, et al. The re­la­tion of serum potas­si­um con­cen­tra­tion with car­dio­vas­cu­lar events and mor­tal­i­ty in com­mu­ni­ty-‍liv­ing in­di­vid­u­als. Clin J Am Soc Nephrol 2017;12:245–252
  66. James MT, Grams ME, Wood­ward M, et al.; CKD Prog­no­sis Con­sor­tium. A meta-‍anal­y­sis of the as­so­ci­a­tion of es­ti­mat­ed GFR, al­bu­min­uria, di­a­betes mel­li­tus, and hy­per­ten­sion with acute kid­ney in­jury. Am J Kid­ney Dis 2015;66: 602–612
  67. Ili­es­cu R, Lohmeier TE, Tu­do­rancea I, Laffin L, Bakris GL. Renal den­er­va­tion for the treat­ment of re­sis­tant hy­per­ten­sion: re­view and clin­i­cal per­spec­tive. Am J Phys­i­ol Renal Phys­i­ol 2015;309: F583–F594
  68. Bakris GL, Agar­w­al R, Chan JC, et al.; Min­er­alo­cor­ti­coid Re­cep­tor An­tag­o­nist Tol­er­a­bil­i­ty Study–Di­a­bet­ic Nephropa­thy (ARTS-‍DN) Study Group. Ef­fect of finerenone on al­bu­min­uria in pa­tients with di­a­bet­ic nephropa­thy: a ran­dom­ized clin­i­cal trial. JAMA 2015;314: 884–894
  69. Williams B, Mac­Don­ald TM, Morant S, et al.; British Hy­per­ten­sion So­ci­ety’s PATH­WAY Stud­ies Group. Spirono­lac­tone ver­sus place­bo, biso­pro­lol, and dox­a­zosin to de­ter­mine the op­ti­mal treat­ment for drug-‍re­sis­tant hy­per­ten­sion (PATH­WAY-‍2): a ran­domised, dou­ble­blind, crossover trial. Lancet 2015;386:2059– 2068
  70. Fi­lip­pa­tos G, Anker SD, Bo¨hm M, et al. A ran­dom­ized con­trolled study of finerenone vs. eplerenone in pa­tients with wors­en­ing chron­ic heart fail­ure and di­a­betes mel­li­tus and/‍or chron­ic kid­ney dis­ease. Eur Heart J 2016; 37:2105–2114
  71. Bom­back AS, Klem­mer PJ. Min­er­alo­cor­ti­coid re­cep­tor block­ade in chron­ic kid­ney dis­ease. Blood Purif 2012;33:119–124
  72. Jensen MD, Ryan DH, Apo­vian CM, et al.; Amer­i­can Col­lege of Car­di­ol­o­gy/Amer­i­can Heart As­so­ci­a­tion Task Force on Prac­tice Guide­lines; Obe­si­ty So­ci­ety. 2013 AHA/‍ACC/‍TOS guide­line for the man­age­ment of over­weight and obe­si­ty in adults: a re­port of the Amer­i­can Col­lege of Car­di­ol­o­gy/Amer­i­can Heart As­so­ci­a­tion Task Force on Prac­tice Guide­lines and The Obe­si­ty So­ci­ety. J Am Coll Car­di­ol 2014;129(25 Suppl. 2): S102–S138
  73. Es­truch R, Ros E, Salas-‍Salvado´ J, et al.;PRED­IMED Study In­ves­ti­ga­tors. Pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar dis­ease with a Mediter­ranean diet sup­ple­ment­ed with extra-‍virgin olive oil or nuts. N Engl J Med 2018;378:e34
  74. Eckel RH, Ja­ki­cic JM, Ard JD, et al. 2013 AHA/ ACC guide­line on lifestyle man­age­ment to re­duce car­dio­vas­cu­lar risk: a re­port of the Amer­i­can Col­lege of Car­di­ol­o­gy/Amer­i­can Heart As­so­ci­a­tion Task Force on Prac­tice Guide­lines. Cir­cu­la­tion 2013;129:S76–S99
  75. Chas­man DI, Posa­da D, Sub­rah­manyan L, Cook NR, Stan­ton VP Jr, Rid­ker PM. Phar­ma­co­ge­net­ic study of statin ther­a­py and choles­terol re­duc­tion. JAMA 2004;291:2821–2827
  76. Meek C, Wierzbic­ki AS, Jewkes C, et al. Daily and in­ter­mit­tent ro­su­vas­tatin 5 mg ther­a­py in­statin in­tol­er­ant pa­tients: an ob­ser­va­tion­al study. Curr Med Res Opin 2012;28:371–378
  77. Mi­haylo­va B, Em­ber­son J, Black­well L, et al.; Choles­terol Treat­ment Tria­lists’ (CTT) Col­lab­o­ra­tors. The ef­fects of low­er­ing LDL choles­terol with statin ther­a­py in peo­ple at low risk of vas­cu­lar dis­ease: meta-‍anal­y­sis of in­di­vid­u­al data from 27 ran­domised tri­als. Lancet 2012; 380:581–590
  78. Baigent C, Keech A, Kear­ney PM, et al.; Choles­terol Treat­ment Tria­lists’ (CTT) Col­lab­o­ra­tors. Efficacy and safe­ty of choles­terol-‍low­er­ing treat­ment: prospec­tivemeta-‍anal­y­sis of­da­ta from 90,056 par­tic­i­pants in 14 ran­domised tri­als of statins. Lancet 2005;366:1267–1278

  79. Py­orala K, Ped­er­sen TR, Kjek­shus J,Faerge­man O, Ols­son AG, Thorgeirs­son G. Choles­terol low­er­ing with sim­vas­tatin im­proves prog­no­sis of di­a­bet­ic pa­tients with coro­nary heart dis­ease. A sub­group anal­y­sis of the Scan­di­na­vian Sim­vas­tatin Sur­vival Study (4S). Di­a­betes Care 1997;20:614–620

  80. Collins R, Ar­mitage J, Parish S, Sleigh P, Peto R; Heart Pro­tec­tion Study Col­lab­o­ra­tive Group. MRC/‍BHF Heart Pro­tec­tion Study of choles­terol-‍low­er­ing with sim­vas­tatin in 5963 peo­ple with di­a­betes: a ran­domised place­bo-‍con­trolled trial. Lancet 2003;361:2005–2016
  81. Gold­berg RB, Mel­lies MJ, Sacks FM, et al.; The Care In­ves­ti­ga­tors. Car­dio­vas­cu­lar events and their re­duc­tion with pravas­tatin in di­a­bet­ic and glu­cose-‍in­tol­er­ant my­ocar­dial in­farc­tion sur­vivors with av­er­age choles­terol lev­els: sub­group anal­y­ses in the Choles­terol and Recur­rent Events (CARE) trial. Cir­cu­la­tion 1998;98:2513– 2519
  82. Shep­herd J, Barter P, Car­me­na R, et al. Ef­fect of low­er­ing LDL choles­terol sub­stan­tially below cur­rently rec­om­mend­ed lev­els in pa­tients with coro­nary heart dis­ease and di­a­betes: the Treat­ing to New Tar­gets (TNT) study. Di­a­betes Care 2006;29:1220–1226
  83. Sever PS, Poul­ter NR, Dahlo¨f B, et al. Re-‍duc­tion in car­dio­vas­cu­lar events with ator­vas­tatin in 2,532 pa­tients with type 2 di­a­betes: Anglo-‍Scan­di­na­vian Car­diac Out­comes Trial– lipid-‍low­er­ing arm (ASCOT-‍LLA). Di­a­betes Care 2005;28:1151–1157
  84. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safe­ty of ator­vas­tatin in the pre­ven­tion of car­dio­vas­cu­lar end points in sub­jects with type 2 di­a­betes: the Ator­vas­tatin Study for Pre­ven­tion of Coro­nary Heart Dis­ease End­points in Non-‍In­sulin-‍Dependent Di­a­betes Mel­li­tus (ASPEN). Di­a­betes Care 2006;29:1478–1485
  85. Col­houn HM, Bet­teridge DJ, Dur­ring­ton PN, et al.; CARDS in­ves­ti­ga­tors. Pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar dis­ease with ator­vas­tatin in type 2 di­a­betes in the Col­lab­o­ra­tive Ator­vas­tatin Di­a­betes Study (CARDS): mul­ti­cen­tre ran­domised place­bo-‍con­trolled trial. Lancet 2004; 364:685–696
  86. Kear­ney PM, Black­well L, Collins R, et al.; Choles­terol Treat­ment Tria­lists’ (CTT) Col­lab­o­ra­tors. Efficacy of choles­terol-‍low­er­ing ther­a­py in 18,686 peo­ple with di­a­betes in 14 ran­domised tri­als of statins: a meta-‍anal­y­sis. Lancet 2008; 371:117–125
  87. Tay­lor F, Huff­man MD, Mace­do AF, et al. Statins for the pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar dis­ease. Cochrane Database Syst Rev 2013; 1:CD004816 Type 1 di­a­betes mel­li­tus and car­dio­vas­cu­lar dis­ease: a sci­en­tificstate­ment from the Amer­i­can Heart As­so­ci­a­tion and Amer­i­can Di­a­betes As­so­ci­a­tion. Cir­cu­la­tion 2014;130:1110–1130
  88. Carter AA, Gomes T, Ca­ma­cho X, Ju­urlink DN, Shah BR, Mam­dan­iMM.Risk of in­ci­dent di­a­betes among pa­tients treat­ed with statins: pop­u­la­tion based study [pub­lished cor­rec­tion ap­pears in BMJ 2013;347:f4356]. BMJ 2013;346:f2610
  89. Baigent C, Black­well L, Em­ber­son J, et al.; Choles­terol Treat­ment Tria­lists’ (CTT) Col­lab­o­ra­tion. Ef­fi­ca­cy and safe­ty of more in­ten­sive low­er­ing of LDL choles­terol: a meta-‍anal­y­sis of data from 170,000 par­tic­i­pants in 26 ran­domised tri­als. Lancet 2010;376:1670–1681
  90. Can­non CP, Blaz­ing MA, Giugliano RP, et al.; IMPROVE-‍IT In­ves­ti­ga­tors. Eze­tim­ibe added to statin ther­a­py after acute coro­nary syn­dromes. N Engl J Med 2015;372:2387–2397
  91. de Fer­ran­ti SD, de Boer IH, Fon­se­ca V, et al. Type 1 di­a­betes mel­li­tus and car­dio­vas­cu­lar dis­ease: a sci­en­tific state­ment from the Amer­i­can Heart As­so­ci­a­tion and Amer­i­can Di­a­betes As­so­ci­a­tion. Cir­cu­la­tion 2014;130:1110–1130
  92. Can­non CP, Braun­wald E, Mc­Cabe CH, et al.; Pravas­tatin or Ator­vas­tatin Eval­u­a­tion and In­fec­tion Ther­a­py-‍Throm­bol­y­sis in My­ocar­dial In­farc­tion 22 In­ves­ti­ga­tors. In­ten­sive ver­sus mod­er­ate lipid low­er­ing with statins after acute coro­nary syn­dromes. N Engl J Med 2004;350: 1495–1504
  93. Saba­tine MS, Giugliano RP, Keech AC, et al.; FOURI­ER Steer­ing Com­mit­tee and In­ves­ti­ga­tors. Evolocum­ab and clin­i­cal out­comes in pa­tients with car­dio­vas­cu­lar dis­ease. N Engl J Med 2017; 376:1713–1722
  94. Giugliano RP, Can­non CP, Blaz­ing MA, et al.; IMPROVE-‍IT (Im­proved Re­duc­tion of Out­comes: Vy­torin Efficacy In­ter­na­tion­al Trial) In­ves­ti­ga­tors. Benefit of adding eze­tim­ibe to statin ther­a­py on car­dio­vas­cu­lar out­comes and safe­ty in pa­tients with ver­sus with­out di­a­betes mel­li­tus: re­sults from IMPROVE-‍IT (Im­proved Re­duc­tion of Out-‍comes: Vy­torin Efficacy In­ter­na­tion­al Trial). Cir­cu­la­tion 2018;137:1571–1582
  95. Mo­ri­ar­ty PM, Ja­cob­son TA, Bruck­ert E, et al. Efficacy and safe­ty of alirocum­ab, a mon­o­clon­al an­ti­body to PCSK9, in statin-‍in­tol­er­ant pa­tients: de­sign and ra­tio­nale of ODYSSEY AL­TER­NA­TIVE, a ran­dom­ized phase 3 trial. J Clin Lipi­dol 2014;8: 554–561
  96. Zhang X-L, Zhu Q-Q, Zhu L, et al. Safe­ty and efficacy of anti-‍PCSK9 an­ti­bod­ies: a meta-‍anal­y­sis of 25 ran­dom­ized, con­trolled tri­als. BMC Med 2015;13:123
  97. Saba­tine MS, Leit­er LA, Wiv­iott SD, et al. Car­dio­vas­cu­lar safe­ty and efficacy of the PCSK9 in­hibitor evolocum­ab in pa­tients with and with­out di­a­betes and the ef­fect of evolocum­ab on gly­caemia and risk of new-‍onset di­a­betes: a pre­specified anal­y­sis of the FOURI­ER ran­domised con­trolled trial. Lancet Di­a­betes En­docrinol 2017;5: 941–950
  98. Berglund L, Brun­zell JD, Gold­berg AC, et al.; En­docrine So­ci­ety. Eval­u­a­tion and treat­ment of hypertriglyc­eridemia: an En­docrine So­ci­ety clin­i­cal prac­tice guide­line. J Clin En­docrinol Metab 2012;97:2969–2989
  99. Singh IM, Shishe­h­bor MH, Ansell BJ. High­den­si­ty lipopro­tein as a ther­a­peu­tic tar­get: a sys­tematic re­view. JAMA 2007;298:786– 798
  100. Keech A, Simes RJ, Barter P, et al.; FIELD study in­ves­ti­ga­tors. Ef­fects of long-‍term feno- fibrate ther­a­py on car­dio­vas­cu­lar events in 9795 peo­ple with type 2 di­a­betes mel­li­tus(the FIELD study): ran­domised con­trolled trial. Lancet 2005;366:1849–1861

     

  101. Jones PH, David­son MH. Re­porting rate of rhab­domy­ol­y­sis with fenofibrate 1 statin ver­sus gemfibrozil 1 any statin. Am J Car­di­ol 2005;95: 120–122
  102. Gins­berg HN, Elam MB, Lo­va­to LC, et al.; AC­CORD Study Group. Ef­fects of com­bi­na­tion lipid ther­a­py in type 2 di­a­betes mel­li­tus. N Engl J Med 2010;362:1563–1574
  103. Kowa Re­search In­sti­tute, Inc. Pemafibrate to Re­duce Car­dio­vas­cu­lar Out­coMes by Re­duc­ing Triglyc­erides IN pa­tiENts With di­a­beTes (PROMI­NENT) In: Clin­i­calTri­als.gov [In­ternet]. Bethes­da, MD, Na­tion­al Li­brary of Medicine.NCT03071692. NLM Iden­tifier: NCT03071692. Ac­cessed 8 Oc­to­ber 2018
  104. Boden WE, Prob­stfield JL, An­der­son T, et al.; AIM-‍HIGH In­ves­ti­ga­tors. Niacin in pa­tients with low HDL choles­terol lev­els re­ceiv­ing in­ten­sive statin ther­a­py. N Engl J Med 2011;365:2255– 2267
  105. Lan­dray MJ, Haynes R, Hopewell JC, et al.; HPS2-‍THRIVE Col­lab­o­ra­tive Group. Ef­fects of ex­tend­ed-‍re­lease niacin with laropiprant in high-‍risk pa­tients. N Engl J Med 2014;371: 203–212
  106. Ra­j­pathak SN, Kumb­hani DJ, Cran­dall J, Barzi­lai N, Al­der­man M, Rid­ker PM. Statin ther­a­py and risk of de­vel­op­ing type 2 di­a­betes: a meta-‍anal­y­sis. Di­a­betes Care 2009;32:1924– 1929
  107. Sat­tar N, Preiss D, Mur­ray HM, et al. Statins and risk of in­ci­dent di­a­betes: a col­lab­o­ra­tive meta-‍anal­y­sis of ran­domised statin tri­als. Lancet 2010;375:735–742
  108. Rid­ker PM, Prad­han A, Mac­Fadyen JG, Libby P, Glynn RJ. Car­dio­vas­cu­lar benefits and di­a­betes risks of statin ther­a­py in pri­ma­ry pre­ven­tion: an anal­y­sis from the JUPITER trial. Lancet 2012;380: 565–571
  109. Mach F, Ray KK, Wik­lund O, et al.; Eu­ro­pean Atheroscle­ro­sis So­ci­ety Con­sen­sus Panel. Ad­verse ef­fects of statin ther­a­py: per­cep­tion vs. the ev­i­dence – focus on glu­cose home­osta­sis, cogni­tive, renal and hep­at­ic func­tion, haem­or­rhag­ic stroke and cataract. Eur Heart J 2018;39: 2526–2539
  110. Heart Pro­tec­tion Study Col­lab­o­ra­tive Group. MRC/‍BHF Heart Pro­tec­tion Study of choles­terol low­er­ing with sim­vas­tatin in 20,536 high-‍risk in­di­vid­u­als: a ran­domised place­bo-‍con­trolled trial. Lancet 2002;360:7–22
  111. Shep­herd J, Blauw GJ, Mur­phy MB, et al.; PROS­PER study group. PROspec­tive Study of Pravas­tatin in the El­der­ly at Risk. Pravas­tatin in el­der­ly in­di­vid­u­als at risk of vas­cu­lar dis­ease (PROS­PER): a ran­domised con­trolled trial. Lancet 2002;360:1623–1630
  112. Trompet S, van Vliet P, de Craen AJM, et al. Pravas­tatin and cogni­tive func­tion in the el­der­ly. Re­sults of the PROS­PER study. J Neu­rol 2010;257: 85–90
  113. Yusuf S, Bosch J, Da­ge­nais G, et al.; HOPE-3 In­ves­ti­ga­tors. Choles­terol low­er­ing in in­ter­me­di­ate-‍risk per­sons with­out car­dio­vas­cu­lar dis­ease. N Engl J Med 2016;374:2021–2031
  114. Giugliano RP, Mach F, Za­vitz K, et al.; EBBING­HAUS In­ves­ti­ga­tors. Cogni­tive func­tion in a ran­dom­ized trial of evolocum­ab. N Engl J Med 2017;377:633–643
  115. Richard­son K, Schoen M, French B, et al. Statins and cogni­tive func­tion: a sys­tematic re­view. Ann In­tern Med 2013;159:688–697
  116. Baigent C, Black­well L, Collins R, et al.; An­tithrom­bot­ic Tria­lists’ (ATT) Col­lab­o­ra­tion. As­pirin in the pri­ma­ry and sec­ondary pre­ven­tion of vas­cu­lar dis­ease: col­lab­o­ra­tive meta-‍anal­y­sis of in­di­vid­u­al par­tic­i­pant data from ran­domised tri­als. Lancet 2009;373:1849–1860
  117. Perk J, De Back­er G, Gohlke H, et al.; Eu­ro­pean As­so­ci­a­tion for Car­dio­vas­cu­lar Pre­ven­tion & Re­ha­bil­i­ta­tion (EACPR); ESC Com­mit­tee for Prac­tice Guide­lines(CPG). Eu­ro­pean Guide­lineson car­dio­vas­cu­lar dis­ease pre­ven­tion in clin­i­cal prac­tice (ver­sion 2012): The Fifth Joint Task Force of the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy and Other So­ci­eties on Car­dio­vas­cu­lar Dis­ease Pre­ven­tion in Clin­i­cal Prac­tice (con­sti­tut­ed by rep­re­sen­ta­tives of nine so­ci­eties and by in­vit­ed ex­perts). Eur Heart J 2012;33:1635–1701
  118. Belch J, Mac­Cuish A, Camp­bell I, et al. The pre­ven­tion of pro­gres­sion of ar­te­ri­al dis­ease and di­a­betes (POPADAD) trial: fac­torial ran­domised place­bo con­trolled trial of as­pirin and an­tiox­i­dants in pa­tients with di­a­betes and asymp­tomat­ic pe­riph­er­al ar­te­ri­al dis­ease. BMJ 2008;337: a1840
  119. Zhang C, Sun A, Zhang P, et al. As­pirin for pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar events in pa­tients with di­a­betes: a meta-‍anal­y­sis. Di­a­betes Res Clin Pract 2010;87:211–218
  120. De Be­rardis G, Sacco M, Strip­poli GFM, et al. As­pirin for pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar events in peo­ple with di­a­betes: metaanal­y­sis of ran­domised con­trolled tri­als. BMJ 2009;339:b4531
  121. AS­CEND Study Col­lab­o­ra­tive Group. Ef­fects of as­pirin for pri­ma­ry pre­ven­tion in per­sons with di­a­betes mel­li­tus. N Engl J Med 2018;379:1529– 1539
  122. Gaziano JM, Bro­tons C, Cop­polec­chia R, et al.; AR­RIVE Ex­ec­u­tive Com­mit­tee. Use of as­pirin to re­duce risk of ini­tial vas­cu­lar events in pa­tients at mod­er­ate risk of car­dio­vas­cu­lar dis­ease (AR­RIVE): a ran­domised, dou­ble-‍blind, place­bo-‍con­trolled trial. Lancet 2018;392:1036– 1046
  123. Mc­Neil JJ, Wolfe R, Woods RL, et al.; AS­PREE In­ves­ti­ga­tor Group. Ef­fect of as­pirin on car­dio­vas­cu­lar events and bleed­ing in the healthy el­der­ly. N Engl J Med 2018;379:1509–1518
  124. Pignone M, Earn­shaw S, Tice JA, Pletch­er MJ. As­pirin, statins, or both drugs for the pri­ma­ry pre­ven­tion of coro­nary heart dis­ease events in men: a cost-‍util­i­ty anal­y­sis. Ann In­tern Med 2006;144:326–336
  125. Pignone M, Al­berts MJ, Col­well JA, et al.; Amer­i­can Di­a­betes As­so­ci­a­tion; Amer­i­can Heart As­so­ci­a­tion; Amer­i­can Col­lege of Car­di­ol­o­gy Foun­da­tion. As­pirin for pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar events in peo­ple with di­a­betes: a po­si­tion state­ment of the Amer­i­can Di­a­betes As­so­ci­a­tion, a sci­en­tific state­ment of the Amer­i­can Heart As­so­ci­a­tion, and an ex­pert con­sen­sus doc­u­ment of the Amer­i­can Col­lege of Car­di­ol­o­gy Foun­da­tion. Di­a­betes Care 2010;33:1395– 1402
  126. Hux­ley RR, Pe­ters SAE, Mishra GD, Wood­ward M. Risk of all-‍cause mor­tal­i­ty and vas­cu­lar events in women ver­sus men with type 1 di­a­betes: a sys­tematic re­view and meta-‍anal­y­sis. Lancet Di­a­betes En­docrinol 2015;3:198–206
  127. Pe­ters SAE, Hux­ley RR, Wood­ward M. Di­a­betes as risk fac­tor for in­ci­dent coro­nary heart dis­ease in women com­pared with men: a sys­tematic re­view and meta-‍anal­y­sis of 64 co­horts in­clud­ing 858,507 in­di­vid­u­als and 28,203 coro­nary events. Di­a­betolo­gia 2014;57:1542– 1551
  128. Kalyani RR, Lazo M, Ouyang P, et al. Sex dif­ferences in di­a­betes and risk of in­ci­dent coro­nary artery dis­ease in healthy young and mid­dle-‍aged adults. Di­a­betes Care 2014;37:830– 838
  129. Pe­ters SAE, Hux­ley RR, Wood­ward M. Di­a­betes as a risk fac­tor for stroke in women com­pared with men: a sys­tematic re­view and meta-‍anal­y­sis of 64 co­horts, in­clud­ing 775,385 in­di­vid­u­als and 12,539 strokes. Lancet 2014;383: 1973–1980
  130. Dimitriu-‍Leen AC, Scholte AJHA, van Rosendael AR, et al. Value of coro­nary com­put­ed to­mog­ra­phy an­giog­ra­phy in tai­loring as­pirin ther­a­py for pri­ma­ry pre­ven­tion of atheroscle­rot­ic events in pa­tients at high risk with di­a­betes mel­li­tus. Am J Car­di­ol 2016;117:887–893
  131. Mora S, Ames JM, Man­son JE. Low-‍dose as­pirin in the pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar dis­ease: shared de­ci­sion mak­ing in clin­i­cal prac­tice. JAMA 2016;316:709–710
  132. Camp­bell CL, Smyth S, Mon­tale­scot G, Stein­hubl SR. As­pirin dose for the pre­ven­tion of car­dio­vas­cu­lar dis­ease: a sys­tematic re­view. JAMA 2007;297:2018–2024
  133. Dav`ı G, Pa­trono C. Platelet ac­ti­va­tion and atherothrom­bo­sis. N Engl J Med 2007;357:2482– 2494
  134. Larsen SB, Grove EL, Neergaard-‍Pe­tersen S, Wu¨rtz M, Hvas A-M, Kris­tensen SD. De­ter­mi­nants of re­duced an­tiplatelet ef­fect of as­pirin in pa­tients with sta­ble coro­nary artery dis­ease. PLoS One 2015;10:e0126767
  135. Za­c­car­di F, Rizzi A, Petruc­ci G, et al. In vivo platelet ac­ti­va­tion and as­pirin re­spon­sive­ness in type 1 di­a­betes. Di­a­betes 2016;65:503–509
  136. Bethel MA, Har­ri­son P, Sourij H, et al. Ran­dom­ized con­trolled trial com­par­ing im­pact on platelet reac­tiv­i­ty of twice-‍daily with once-‍daily as­pirin in peo­ple with type 2 di­a­betes. Di­a­bet Med 2016;33:224–230
  137. Roth­well PM, Cook NR, Gaziano JM, et al. Ef­fects of as­pirin on risks of vas­cu­lar events and can­cer ac­cord­ing to body­weight and dose: anal­y­sis of in­di­vid­u­al pa­tient data from ran­domised tri­als. Lancet 2018;392:387–399
  138. Vand­vik PO, Lin­coff AM, Gore JM, et al. Pri­ma­ry and sec­ondary pre­ven­tion of car­dio­vas­cu­lar dis­ease: An­tithrom­bot­ic Ther­a­py and Pre­ven­tion of Throm­bo­sis, 9th ed: Amer­i­can Col­lege of Chest Physi­cians Ev­i­dence-‍Based Clin­i­cal Prac­tice Guide­lines [pub­lished cor­rec­tion ap­pears inCh­est 2012;141:1129]. Chest 2012;141(Suppl.): e637S–e668S
  139. Bhatt DL, Bonaca MP, Ban­si­lal S, et al. Re­duc­tion in is­chemic events with tica­grelor in di­a­bet­ic pa­tients with prior my­ocar­dial in­farc­tion in PEGASUS-‍TIMI 54. J Am Coll Car­di­ol 2016;67:2732–2740
  140. Bax JJ, Young LH, Frye RL, Bonow RO, Stein­berg HO, Bar­rett EJ. Screen­ing for coro­nary artery dis­ease in pa­tients with di­a­betes. Di­a­betes Care 2007;30:2729–2736
  141. Boden WE, O’Rourke RA, Teo KK, et al.; COURAGE Trial Re­search Group. Op­ti­mal med­i­cal ther­a­py with or with­out PCI for sta­ble coro­nary dis­ease. N Engl J Med 2007;356:1503–1516
  142. BARI 2D Study Group, Frye RL, Au­gust P, et al. A ran­dom­ized trial of ther­a­pies for type 2 di­a­betes and coro­nary artery dis­ease. N Engl J Med 2009;360:2503–2015
  143. Wack­ers FJT, Chyun DA, Young LH, et al.; De­tec­tion of Is­chemia in Asymp­tomat­ic Di­a­bet­ics (DIAD) In­ves­ti­ga­tors. Res­o­lu­tion of asymp­tomat­ic my­ocar­dial is­chemia in pa­tients with type 2 di­a­betes in the De­tec­tion of Is­chemia in Asymp­tomat­ic Di­a­bet­ics (DIAD) study. Di­a­betes Care 2007;30:2892–2898
  144. Elke­les RS, God­s­land IF, Feher MD, et al.; PRE­DICT Study Group. Coro­nary cal­ci­um mea­sure­ment im­proves pre­dic­tion of car­dio­vas­cu­lar events in asymp­tomat­ic pa­tients with type 2 di­a­betes: the PRE­DICT study. Eur Heart J 2008; 29:2244–2251
  145. Raggi P, Shaw LJ, Berman DS, Cal­lis­ter TQ. Prog­nos­tic value of coro­nary artery cal­ci­um screen­ing in sub­jects with and with­out di­a­betes. J Am Coll Car­di­ol 2004;43:1663–1669
  146. Anand DV, Lim E, Hop­kins D, et al. Risk stratification in un­com­pli­cat­ed type 2 di­a­betes: prospec­tive eval­u­a­tion of the com­bined use of coro­nary artery cal­ci­um imag­ing and se­lec­tive my­ocar­dial per­fu­sion scintig­ra­phy. Eur Heart J 2006;27:713–721
  147. Young LH, Wack­ers FJT, Chyun DA, et al.; DIAD In­ves­ti­ga­tors. Car­diac out­comes after screen­ing for asymp­tomat­ic coro­nary artery dis­ease in pa­tients with type 2 di­a­betes: the DIAD study: a ran­dom­ized con­trolled trial. JAMA 2009;301:1547–1555
  148. Wack­ers FJT, Young LH, In­zuc­chi SE, et al.; De­tec­tion of Is­chemia in Asymp­tomat­ic Di­a­bet­ics In­ves­ti­ga­tors. De­tec­tion of silent my­ocar­dial is­chemia in asymp­tomat­ic di­a­bet­ic sub­jects: the DIAD study. Di­a­betes Care 2004;27:1954–1961
  149. Scog­namiglio R, Negut C, Ra­mon­do A, Tien­go A, Avog­a­ro A. De­tec­tion of coro­nary artery dis­ease in asymp­tomat­ic pa­tients with type 2 di­a­betes mel­li­tus. J Am Coll Car­di­ol 2006; 47:65–71
  150. Hadamitzky M, Hein F, Meyer T, et al. Prog­nos­tic value of coro­nary com­put­ed to­mo­graph­ic an­giog­ra­phy in di­a­bet­ic pa­tients with­out known coro­nary artery dis­ease. Di­a­betes Care 2010;33:1358–1363
  151. Choi E-K, Chun EJ, Choi S-I, et al. As­sess­ment of subclin­i­cal coro­nary atheroscle­ro­sis in asymp­tomat­ic pa­tients with type 2 di­a­betes mel­li­tus with sin­gle pho­ton emis­sion com­put­ed to­mog­ra­phy and coro­nary com­put­ed to­mog­ra­phy an­giog­ra­phy. Am J Car­di­ol 2009;104:890–896
  152. Malik S, Zhao Y, Bud­off M, et al. Coro­nary artery cal­ci­um score for long-‍term risk clas­sification in in­di­vid­u­als with type 2 di­a­betes and metabol­ic syn­drome from the Multi-‍Eth­nic Study of Atheroscle­ro­sis. JAMA Car­di­ol 2017;2:1332–1340
  153. Wing RR, Bolin P, Bran­cati FL, et al.; Look AHEAD Re­search Group. Car­dio­vas­cu­lar ef­fects of in­ten­sive lifestyle in­ter­ven­tion in type 2 di­a­betes. N Engl J Med 2013;369:145–154
  154. Braun­wald E, Do­man­s­ki MJ, Fowler SE, et al.; PEACE Trial In­ves­ti­ga­tors. An­giotensin-‍con­vert­ing-‍en­zyme in­hi­bi­tion in sta­ble coro­nary artery dis­ease. N Engl J Med 2004;351:2058– 2068
  155. Telmis­ar­tan Ran­domised As­sess­meNt Study in ACE iN­tol­er­ant sub­jects with car­dio­vas­cu­lar

    Dis­ease (TRAN­SCEND) In­ves­ti­ga­tors, Yusuf S, Teo K, et al. Ef­fects of the an­giotensin-‍re­cep­tor block­er telmis­ar­tan on car­dio­vas­cu­lar events in high-‍risk pa­tients in­tol­er­ant to an­giotensin-converting en­zyme in­hibitors: a ran­domised con­trolled trial. Lancet 2008;372:1174–1183

  156. Kez­erashvili A, Marzo K, De Leon J. Beta block­er use after acute my­ocar­dial in­farc­tion in the pa­tient with nor­mal sys­tolic func­tion: when is it “ok” to dis­con­tin­ue? Curr Car­di­ol Rev 2012;8:77–84
  157. U.S. Food and Drug Ad­min­is­tra­tion. Guid­ance for in­dus­try. Di­a­betes mel­li­tusdeval­u­at­ing car­dio­vas­cu­lar risk in new antidi­a­bet­ic ther­a­pies to treat type 2 di­a­betes [In­ternet]. Sil­ver Spring, MD, 2008. Avail­able from http://www.fda.gov/‍downloads/‍ Drugs/Guid­anceComplianceRegulatoryInformation/ Guid­ances/ucm071627.pdf). Ac­cessed 3 Novem­ber 2017
  158. Neal B, Perkovic V, Matthews DR, et al.; CAN­VAS-‍R Trial Col­lab­o­ra­tive Group. Ra­tio­nale, de­sign and base­line char­ac­ter­is­tics of the CANagliflozin cardioVas­cu­lar As­sess­ment Study-‍ Renal (CAN­VAS-‍R): a ran­dom­ized, place­bo-‍con­trolled trial. Di­a­betes Obes Metab 2017; 19:387–393
  159. Marso SP, Daniels GH, Brown-‍Frand­sen K, et al.; LEAD­ER Steer­ing Com­mit­tee; LEAD­ER Trial In­ves­ti­ga­tors. Li­raglu­tide and car­dio­vas­cu­lar out-‍comes in type 2 di­a­betes. N Engl J Med 2016;375: 311–322
  160. Marso SP, Bain SC, Con­soli A, et al.; SUSTAIN-‍6 In­ves­ti­ga­tors. Semaglu­tide and car­dio­vas­cu­lar out­comes in pa­tients with type 2 di­a­betes. N Engl J Med 2016;375:1834–1844
  161. Pf­ef­fer MA, Claggett B, Diaz R, et al.; ELIXA In­ves­ti­ga­tors. Lixise­n­atide in pa­tients with type 2 di­a­betes and acute coro­nary syn­drome. N Engl J Med 2015;373:2247–2257
  162. Hol­man RR, Bethel MA, Mentz RJ, et al.; EXS­CEL Study Group. Ef­fects of once-‍week­ly ex­e­natide on car­dio­vas­cu­lar out­comes in type 2 di­a­betes. N Engl J Med 2017;377:1228–1239
  163. Her­nan­dez AF, Green JB, Jan­mo­hamed S, et al.; Har­mo­ny Out­comes com­mit­tees and in­ves­ti­ga­tors. Al­biglu­tide and car­dio­vas­cu­lar out-‍comes in pa­tients with type 2 di­a­betes and car­dio­vas­cu­lar dis­ease (Har­mo­ny Out­comes): a dou­ble-‍blind, ran­domised place­bo-‍con­trolled trial. Lancet 2018;392:1519–1529
  164. Kan­nel WB, Hjort­land M, Castel­li WP. Role of di­a­betes in con­ges­tive heart fail­ure: the Fram­ing­ham study. Am J Car­di­ol 1974;34: 29–34
  165. Dor­mandy JA, Char­bon­nel B, Eck­land DJA, et al.; PROac­tive In­ves­ti­ga­tors. Sec­ondary pre­ven­tion of macrovas­cu­lar events in pa­tients with type 2 di­a­betes in the PROac­tive Study (PROspec­tive pi­ogli­tA­zone Clin­i­cal Trial In macroVas­cu­lar Events): a ran­domised con­trolled trial. Lancet 2005;366:1279–1289
  166. Singh S, Loke YK, Furberg CD. Long-‍term risk of car­dio­vas­cu­lar events with rosigli­ta­zone: a meta-‍anal­y­sis. JAMA 2007;298:1189–1195
  167. Lin­coff AM, Wol­s­ki K, Nicholls SJ, Nis­sen SE. Pi­ogli­ta­zone and risk of car­dio­vas­cu­lar events in pa­tients with type 2 di­a­betes mel­li­tus: a metaanal­y­sis of ran­dom­ized tri­als. JAMA 2007;298: 1180–1188
  168. Scir­i­ca BM, Bhatt DL, Braun­wald E, et al.; SAVOR-‍TIMI 53 Steer­ing Com­mit­tee and In­ves­ti­ga­tors. Saxagliptin and car­dio­vas­cu­lar out­comes in pa­tients with type 2 di­a­betes mel­li­tus. N Engl J Med 2013;369:1317–1326
  169. U.S. Food and Drug Ad­min­is­tra­tion. FDA Drug Safe­ty Com­mu­ni­ca­tion: FDA adds warn­ings about heart fail­ure risk to la­bels of type 2 di­a­betes medicines con­tain­ing saxagliptin and alogliptin [In­ternet], 2016. Avail­able from http:// www.fda.gov/Drugs/DrugSafe­ty/ucm486096.htm. Ac­cessed 24 Septem­ber 2018
  170. Zan­nad F, Can­non CP, Cush­man WC, et al.; EX­AM­INE In­ves­ti­ga­tors. Heart fail­ure and mor­tal­i­ty out­comes in pa­tients with type 2 di­a­betes tak­ing alogliptin ver­sus place­bo in EX­AM­INE: a mul­ti­cen­tre, ran­domised, dou­ble-‍blind trial. Lancet 2015;385:2067–2076
  171. Green JB, Bethel MA, Arm­strong PW, et al.; TECOS Study Group. Ef­fect of sitagliptin on car­dio­vas­cu­lar out­comes in type 2 di­a­betes. N Engl J Med 2015;373:232–242
  172. Fitch­ett D, But­ler J, van de Borne P, et al. Ef­fects of em­pagliflozin on risk for car­dio­vas­cu­lar death and heart fail­ure hos­pi­tal­iza­tion across the spec­trum of heart fail­ure risk in the EMPA-‍REG OUT­COME trial. Eur Heart J 2017;39:363–370
  173. Hans­son L, Zanchet­ti A, Car­ruthers SG, et al.; HOT Study Group. Ef­fects of in­ten­sive blood-‍pres­sure low­er­ing and low-‍dose as­pirin in pa­tients with hy­per­ten­sion: prin­ci­pal re­sults of the Hy­per­ten­sion Op­ti­mal Treat­ment (HOT) ran­domised trial. Lancet 1998;351:1755–1762
  174. Zoun­gas S, Chalmers J, Neal B, et al.; AD­VANCE-‍ON Col­lab­o­ra­tive Group. Fol­low-‍up of blood-‍pres­sure low­er­ing and glu­cose con­trol in type 2 di­a­betes. N Engl J Med 2014;371:1392–1406
  175. White WB, Can­non CP, Heller SR, et al.; EX­AM­INE In­ves­ti­ga­tors. Alogliptin after acute coro­nary syn­drome in pa­tients with type 2 di­a­betes. N Engl J Med 2013;369:1327–1335
  176. Ce­falu WT, Kaul S, Ger­stein HC, et al. Car­dio­vas­cu­lar out­comes tri­als in type 2 di­a­betes: where do we go from here? Reflec­tions from a Di­a­betes Care Ed­i­tors’ Ex­pert Forum. Di­a­betes Care 2018;41:14–31